Proteon Therapeutics announced a long-term contract extension with Lonza Pharma & Biotech for the commercial supply of investigational vonapanitase’s active pharmaceutical ingredient (API). “Proteon and Lonza have had a strong relationship for nearly a decade, and this amendment extends that relationship,” said Timothy Noyes, president and chief executive officer of Proteon. “The amendment provides Proteon with access to a top-tier manufacturing site for the long-term commercial suppl...